Previous close | 66.79 |
Open | 65.00 |
Bid | 65.52 x 200 |
Ask | 65.64 x 200 |
Day's range | 63.63 - 66.48 |
52-week range | 44.20 - 82.04 |
Volume | |
Avg. volume | 716,433 |
Market cap | 7.134B |
Beta (5Y monthly) | 0.94 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte Inc (NASDAQ:PCVX), has sold 8,000 shares of the company on March 18, 2024, according to a recent SEC filing.